Linrodostat (development code BMS-986205) is an experimental drug being studied for its immunomodulating and antineoplastic activities.[1]
Linrodostat is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1).[2][3]
Linrodostat has entered clinical trials for a variety of cancer types including bladder cancer, head and neck cancer,
endometrial cancer, gastric cancer, malignant melanoma, liver cancer, non-small cell lung cancer, and solid tumors.[4]
^"Linrodostat". NCI Drug Dictionary. National Cancer Institute.
^Balog A, Lin TA, Maley D, Gullo-Brown J, Kandoussi EH, Zeng J, Hunt JT (March 2021). "Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor". Molecular Cancer Therapeutics. 20 (3): 467–476. doi:10.1158/1535-7163.MCT-20-0251. PMID 33298590. S2CID 228087398.
^"IDO Inhibitor Development Shows Fresh Signs of Life Across Tumor Types". onclive.com. October 31, 2019.
Linrodostat (development code BMS-986205) is an experimental drug being studied for its immunomodulating and antineoplastic activities. Linrodostat is...